Monday, February 12, 2024 6:39:11 AM
Maxim Group LLC is acting as the sole placement agent for the offering.
The offering is expected to close on or about January 30, 2024, subject to the satisfaction of customary closing conditions.
Recent ICU News
- SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure • GlobeNewswire Inc. • 04/30/2024 12:30:00 PM
- SeaStar Medical Reports 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 04/17/2024 08:00:00 PM
- SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 12:30:00 PM
- SeaStar Medical to Restate Financials, Sets Business Update Call for April 17 • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients • GlobeNewswire Inc. • 03/12/2024 12:30:00 PM
- SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024 • GlobeNewswire Inc. • 03/11/2024 08:05:00 PM
- Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
- Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™ • GlobeNewswire Inc. • 02/22/2024 12:58:00 PM
- FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury • GlobeNewswire Inc. • 02/22/2024 12:53:00 PM
- SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology • GlobeNewswire Inc. • 02/01/2024 01:30:00 PM
- SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market • GlobeNewswire Inc. • 01/26/2024 01:05:00 PM
- SeaStar Medical Appoints David A. Green as Chief Financial Officer • GlobeNewswire Inc. • 01/11/2024 09:05:00 PM
- SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications • GlobeNewswire Inc. • 01/09/2024 01:30:00 PM
- SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury • GlobeNewswire Inc. • 12/28/2023 01:30:00 PM
- SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts • GlobeNewswire Inc. • 12/13/2023 01:30:00 PM
- SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 11/14/2023 09:04:00 PM
- Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device • GlobeNewswire Inc. • 10/31/2023 12:00:00 PM
- FDA Issues Approvable Letter for SeaStar Medical’s Selective Cytopheretic Device for Pediatric Patients • GlobeNewswire Inc. • 10/30/2023 12:00:00 PM
- FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome • GlobeNewswire Inc. • 10/18/2023 12:30:00 PM
- SeaStar Medical to Present at the Dawson James Small Cap Growth Conference on October 12, 2023 • GlobeNewswire Inc. • 10/05/2023 12:30:00 PM
- SeaStar Medical Provides Regulatory Update Regarding Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption • GlobeNewswire Inc. • 10/03/2023 08:05:00 PM
- FDA Grants Breakthrough Device Designation to SeaStar Medical’s Selective Cytopheretic Device for Cardiorenal Syndrome • GlobeNewswire Inc. • 09/29/2023 12:30:00 PM
- Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference • GlobeNewswire Inc. • 09/21/2023 01:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2023 08:35:26 PM
- Case Series of Three Critically Ill Children with Acute Kidney Injury Safely Treated with SeaStar Medical’s Selective Cytopheretic Device Published in the Journal Blood Purification • GlobeNewswire Inc. • 08/29/2023 12:00:00 PM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM